A study to test whether PF-05221304 and PF-06865571 caused any medical problems and if they were able to lower levels of liver fat when taken alone or together by patients with Non-Alcoholic Fatty Liver Disease (NAFLD). A Phase 2a, Randomized, Double Blind (Sponsor-Open), Placebo Controlled, Parallel Group Study to Assess the Pharmacodynamics, Safety, and Tolerability of PF- 05221304 and PF-06865571 Co-Administered for 6 Weeks in Adults With Non-Alcoholic Fatty Liver Disease (NAFLD).